Displaying drugs 12351 - 12375 of 12696 in total
Name | Weight | Structure | Description | Categories |
---|---|---|---|---|
Varespladib | 380.4 C21H20N2O5 | Varespladib has been investigated for the treatment and prevention of Sickle Cell Disease, Vaso-occlusive Crisis, and Acute Coronary Syndrome. | Phospholipase A2 Inhibitors / Phospholipases A, antagonists & inhibitors | |
Varespladib methyl | 394.427 C22H22N2O5 | Investigated for use/treatment in atherosclerosis and coronary artery disease. | Phospholipase A2 Inhibitors | |
Variolin B | 293.2834 C14H11N7O | Not Available | Alkaloids | |
Varlitinib | 466.94 C22H19ClN6O2S | Investigated for use/treatment in cancer/tumors (unspecified). | Heterocyclic Compounds, Fused-Ring / Sulfur Compounds | |
Varoglutamstat | 336.395 C19H20N4O2 | Not Available | Not Available | |
Vasoactive intestinal peptide | 3326.83 C147H237N43O43S | Not Annotated | Gastrointestinal Agents / Neuroprotective Agents / Vasodilating Agents | |
Vasomera | Not Available | Not Available | Experimental Unapproved Treatments for COVID-19 / Vasodilating Agents | |
Vasopressin | 2140.46 C92H130N28O24S4 | A peptide hormone used to increase blood pressure in patients with vasodilatory shock who are resistant to fluid and catecholamine therapy. | Vasopressin and Analogues | |
Vatalanib | 346.813 C20H15ClN4 | Used in combination with first- and second-line chemotherapy for the treatment of metastatic colorectal cancer and non-small cell lung cancer (NSCLC). | Protein Kinase Inhibitors | |
Vatiquinone | 440.668 C29H44O3 | Vatiquinone has been investigated for the treatment and prevention of Retinopathy, Rett Syndrome, Genetic Disease, Noise-induced Hearing Loss, and Methylmalonic Aciduria and Homocystinuria,Cblc Type. | Benzoquinones / Coenzymes / Enzymes and Coenzymes / Quinones | |
VB-201 | 581.772 C29H60NO8P | VB-201 is under investigation in clinical trial NCT01001468 (Study to Assess VB-201 in Patients With Psoriasis). | Alcohols / Carbohydrates / Glycerophosphates / Glycerophospholipids / Lecithins / Lipids / Membrane Lipids / Phosphatidic Acids / Phosphatidylcholines / Phospholipids / Plant Extracts / Sugar Alcohols / Triose Sugar Alcohols | |
VB-309 | 638.751 C33H50O12 | Not Annotated | Cannabinoids and similars | |
VB-310 | 638.751 C33H50O12 | Not Annotated | Cannabinoids and similars | |
VB-311 | 800.892 C39H60O17 | Not Annotated | Cannabinoids and similars | |
VB-312 | 800.892 C39H60O17 | Not Annotated | Cannabinoids and similars | |
VB-313 | 963.033 C45H70O22 | Not Annotated | Cannabinoids and similars | |
Vebicorvir | 467.44 C19H12F3N3O4S2 | Not Available | Not Available | |
Vebreltinib | 424.391 C20H15F3N8 | Not Annotated | Not Annotated | |
Vecabrutinib | 529.92 C22H24ClF4N7O2 | Vecabrutinib is under investigation in clinical trial NCT03037645 (Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers). | Amines | |
Vecuronium | 557.8274 C34H57N2O4 | A nondepolarizing neuromuscular blocking agent used to relax muscles or as an adjunct in general anesthesia during surgical procedures. | Androstanols / Neuromuscular-Blocking Agents (Nondepolarizing) / Nicotinic Antagonists | |
Vedroprevir | 910.53 C45H60ClN7O9S | Vedroprevir has been investigated for the treatment of Hepatitis C, Chronic. | Antiviral Agents | |
VEGFR 2 Kinase inhibitor I | 310.353 C18H18N2O3 | Not Annotated | Not Annotated | |
VEGFR2-169 | 1073.224 C47H76N16O13 | VEGFR2-169 is under investigation in clinical trial NCT00655785 (Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer (Phase1/2)). | Cancer Vaccines / Vaccines, Subunit | |
Veglin | Not Available | Investigated for use/treatment in cancer/tumors (unspecified) and solid tumors. | Not Available | |
Velafermin | Not Annotated | Investigated for use/treatment in adverse effects (chemotherapy). | Amino Acids, Peptides, and Proteins / Biological Factors / Intercellular Signaling Peptides and Proteins / Peptides / Proteins |
Displaying drugs 12351 - 12375 of 12696 in total